Since TKI treatment of the ALK-translocated NSCLC H3122 cells induced high expression of ALDH1 in vitro and increased tumorigenesis in vivo, it was necessary to ascertain whether this is a general phenomenon in targeted therapy-sensitive cancer cell lines. This evidence concerns the gene ALDH1A1 and non-small cell lung carcinoma.